Monevis vs DNA Funded

Side-by-side comparison of trust scores, profit splits, payout speed, and real trader reviews. Independent data — no sponsored rankings.

MONEVIS DETAILS

+Profit split of 85% is above the industry average of 84.7%, giving traders a slightly better earnings share.
+Min challenge cost of $49 is well below the industry average of $186.7, making entry highly affordable.
+Weekend holding, news trading, and EA/automated trading are all permitted, supporting diverse trading approaches.
+On-demand payouts provide traders with maximum flexibility in withdrawing earned profits.

−Max funding of $400,000 is well below the industry average of $839,272.7, limiting overall earning potential.
−Overall drawdown of 8% slightly exceeds the industry average of 7.9%, offering marginally less buffer.
−Founded in 2023, Monevis has a limited track record, which may concern traders prioritising firm stability.

+No performance data is available to identify any above-average metrics for this firm
+No fee, payout, or structure data provided to evaluate competitiveness
+No platform or market data available to assess trading flexibility
+Country of operation (Australia) is noted, but no regulatory or structural data exists

−No data is provided for this firm, making any meaningful comparison impossible
−Traders cannot assess profit split, funding, or costs against the 84.7% and $186.7 averages
−Complete absence of data is a significant transparency concern for traders making financial decisions

Monevis

Higher trust score (58/100). Faster payouts at 7d. 85% profit split.

DNA Funded

Lower trust score (0/100). Slower payouts at —d.